CytomX Therapeutics, Inc. has recently come into the spotlight following a filing by State Street Corporation, which disclosed a beneficial ownership of 9,025,855 shares of CytomX's common stock. This stake represents approximately 4.1% of the company's total shares. The filing, submitted on November 10, 2026, under Schedule 13G, indicates State Street's ongoing interest in CytomX, a company involved in the pharmaceutical preparations sector.

Background

CytomX Therapeutics, Inc. operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker CTMX. As an accelerated filer, CytomX has been active in the market, with recent filings including a 10-Q report and an 8-K disclosure on November 5, 2026. The company is headquartered at 151 Oyster Point Blvd, Suite 400, South San Francisco, California.

What the Filing Says

The recent Schedule 13G filing reveals that State Street Corporation holds a total of 9,025,855 shares, with shared voting power of 8,753,246 shares. The filing states, "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." This assertion emphasizes that State Street's investment is not aimed at altering CytomX's management or operational strategies.

Impact

This substantial stake by State Street Corporation could have various implications for CytomX and the broader pharmaceutical preparations industry. Investors and analysts may interpret this as a vote of confidence in CytomX's future prospects, potentially attracting more attention from institutional investors. Additionally, State Street's involvement could influence the company's strategic decisions moving forward, depending on how they choose to exercise their voting power.

What's Next

The filing does not specify any immediate actions or next steps following this disclosure. However, the market will likely monitor any further developments or changes in State Street's ownership stake in CytomX.